Mediclinic Middle East Site Visit

David Hadley, Mediclinic Middle East CEO, will briefly present an overview of the division focusing on the following key areas:

− Mediclinic’s position as a leading private healthcare provider in the UAE
− Attractive long-term market fundamentals in the UAE
− Delivery of superior international standards in patient experience and clinical excellence
− Expansion opportunities and sustainable long-term growth
− Future plans across the continuum of care

Guidance for Mediclinic Middle East remains unchanged. The division expects to deliver FY19 revenue growth (adjusted for the adoption of IFRS 15) in the high single-digit percentage range reflecting the underlying operating performance of the business and additional bed capacity coming online in the second half of the year. The operating leverage in the underlying business, offset to some extent by the start-up losses associated with expansion projects, is expected to deliver a slightly improved EBITDA margin compared to the prior year (adjusted for the adoption of IFRS 15, FY18: 13.0%). The Group continues to expect ongoing EBITDA margin expansion to around 20% by FY23 given the ongoing improvements and expansion opportunities across the region.

No new material information will be provided during the event. Presentation material will be made available online shortly after 7am GMT, here: https://ir.mediclinic.com/resultscentre/presentations-and-investor-days.

About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with current operating divisions in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UKbased private healthcare group.

Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden operates 18 private hospitals and 4 clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 48 hospitals and 4 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 7 hospitals and 22 clinics with more than 900 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

The divisions' contributions to Group revenue for the financial year ended 31 March 2018 were 47% by Hirslanden, 31% by Mediclinic Southern Africa and 22% by Mediclinic Middle East.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott
– UK +44 (0)20 3727 1000

Sherryn Schooling
– South Africa +27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham St., London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd